{
  "id": 10881154,
  "title": "Molbio Diagnostics shares rally 9% as Jefferies initiates 'high conviction top pick' call for recently listed stock. Why is it bullish?",
  "url": "https://urgent.news/2026/09/30/molbio-diagnostics-shares-rally-9-as-jefferies-initiates-high",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-30T05:54:26.000Z",
  "source": {
    "name": "The Economic Times - Top News",
    "slug": "the-economic-times-top-news",
    "url": "https://economictimes.indiatimes.com/markets/stocks/news/molbio-diagnostics-shares-rally-9-as-jefferies-initiates-high-conviction-top-pick-call-for-recently-listed-stock-why-is-it-bullish/articleshow/134582706.cms"
  },
  "original_language": "en",
  "account": "Molbio Diagnostics' stock surged over 9% on Wednesday following Jefferies' decision to initiate coverage on the newly listed company with a high conviction top pick rating. This bullish sentiment stems from Jefferies’ assessment that Molbio is an innovation-led medical technology firm, focusing on developing next-generation diagnostic platforms to tackle significant healthcare issues. The brokerage maintains that Molbio is among the rare Indian innovation-driven companies that have already demonstrated success with its flagship Truenat platform, along with several more products in the pipeline for long-term growth.",
  "summary": "Molbio Diagnostics shares jumped after Jefferies initiated coverage with a Buy rating and named it a high-conviction top pick. The brokerage set a Rs 1,600 target price, implying 27% upside from Tuesday’s close and nearly 98% above its Rs 807 IPO price. The stock had listed at a 21% premium at Rs 980.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}